AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation

Abstract Background Recent findings suggest that αE expression is enriched on effector T cells and that intestinal αE+ T cells have increased expression of inflammatory cytokines. αE integrin expression is a potential predictive biomarker for response to etrolizumab, a monoclonal antibody against β7 integrin that targets both α4β7 and αEβ7. We evaluated the prevalence and localization of αE+ cells as well as total αE gene expression in healthy and inflammatory bowel disease patients. Methods αE+ cells were identified in ileal and colonic biopsies by immunohistochemistry and counted using an automated algorithm. Gene expression was assessed by quantitative reverse-transcriptase polymerase chain reaction. Results In both healthy and inflammatory bowel disease patients, significantly more αE+ cells were present in the epithelium and lamina propria of ileal compared with colonic biopsies. αE gene expression levels were also significantly higher in ileal compared with colonic biopsies. Paired biopsies from the same patient showed moderate correlation of αE expression between the ileum and colon. Inflammation did not affect αE expression, and neither endoscopy nor histology scores correlated with αE gene expression. αE expression was not different between patients based on concomitant medication use except 5-aminosalicylic acid. Conclusion αE+ cells, which have been shown to have inflammatory potential, are increased in the ileum in comparison with the colon in both Crohn’s disease and ulcerative colitis, as well as in healthy subjects. In inflammatory bowel disease patients, αE levels are stable, regardless of inflammatory status or most concomitant medications, which could support its use as a biomarker for etrolizumab.

[1]  J. Mansfield,et al.  αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis , 2016, Journal of Crohn's & colitis.

[2]  M. Keir,et al.  Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC , 2016, Gut.

[3]  M. Neurath,et al.  Blockade of αEβ7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo , 2016, Gut.

[4]  John T. Chang,et al.  The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium , 2016, The American Journal of Gastroenterology.

[5]  Stefan Schreiber,et al.  Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. , 2016, Gastroenterology.

[6]  B. Yaspan,et al.  Stratified medicine in inflammatory disorders: From theory to practice. , 2015, Clinical immunology.

[7]  L. Stitt,et al.  Development and validation of a histological index for UC , 2015, Gut.

[8]  S. Vermeire,et al.  901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study , 2015 .

[9]  John T. Chang,et al.  Validation of Gene Expression Biomarker Analysis for Biopsy-based Clinical Trials in Crohn's Disease , 2015, Inflammatory bowel diseases.

[10]  M. Groenen,et al.  Naive T Cells in the Gut of Newly Diagnosed, Untreated Adult Patients with Inflammatory Bowel Disease , 2014, Inflammatory bowel diseases.

[11]  J. Xu,et al.  Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. , 2014, Gastroenterology.

[12]  J. Mansfield,et al.  Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial , 2014, The Lancet.

[13]  J. Fletcher,et al.  EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging , 2013, The American Journal of Gastroenterology.

[14]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[15]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[16]  A. Huisman,et al.  Automatic Nuclei Segmentation in H&E Stained Breast Cancer Histopathology Images , 2013, PloS one.

[17]  M. Colonna,et al.  Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells. , 2013, Immunity.

[18]  W. Agace,et al.  Targeting T‐cell migration in inflammatory bowel disease , 2012, Journal of internal medicine.

[19]  K. Ley,et al.  Role of beta7 integrins in intestinal lymphocyte homing and retention. , 2009, Current molecular medicine.

[20]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[21]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[22]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[23]  P. Rutgeerts,et al.  Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. , 2004, Gastrointestinal endoscopy.

[24]  Y. Fujiwara,et al.  Differential expression of homing receptor CD103 on lamina propria lymphocytes and association of CD103 with epithelial adhesion molecules in inflammatory bowel disease. , 2003, International journal of molecular medicine.

[25]  B. Rocha,et al.  A unique subpopulation of CD4+ regulatory T cells controls wasting disease, IL‐10 secretion and T cell homeostasis , 2003, European journal of immunology.

[26]  Larry V McIntire,et al.  Automated Selection of DAB-labeled Tissue for Immunohistochemical Quantification , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[27]  J. Kirby,et al.  The number of intraepithelial T cells decreases from ascending colon to rectum. , 2003, Journal of clinical pathology.

[28]  Richard O Hynes,et al.  Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.

[29]  Alf Hamann,et al.  Expression of the integrin αEβ7 identifies unique subsets of CD25+ as well as CD25− regulatory T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  H. Van Vlierberghe,et al.  Altered expression of alpha E beta 7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn's disease. , 1998, Acta gastro-enterologica Belgica.

[31]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[32]  R. Johnson,et al.  Characterization of gut-associated lymphoid tissue (GALT) of normal rhesus macaques. , 1997, Clinical immunology and immunopathology.

[33]  E. Ebert,et al.  Spontaneous cytotoxicity of intestinal intraepithelial lymphocytes: clues to the mechanism , 1993, Clinical and experimental immunology.

[34]  T. Arndt,et al.  In vivo , 2019, Springer Reference Medizin.

[35]  B. Sands,et al.  Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease. , 2018, Gastroenterology.

[36]  B. Sands,et al.  Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy , 2017, Inflammatory bowel diseases.

[37]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[38]  B. Warner,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[39]  E. Szigethy,et al.  Inflammatory bowel disease. , 2011, Pediatric clinics of North America.

[40]  A. Scheffold,et al.  Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. , 2002, Proceedings of the National Academy of Sciences of the United States of America.